scholarly journals A DNA methylation-based definition of biologically distinct breast cancer subtypes

2014 ◽  
Vol 9 (3) ◽  
pp. 555-568 ◽  
Author(s):  
Olafur A. Stefansson ◽  
Sebastian Moran ◽  
Antonio Gomez ◽  
Sergi Sayols ◽  
Carlos Arribas-Jorba ◽  
...  
2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1041-1041
Author(s):  
Joaquina Martínez-Galan ◽  
Sandra Rios ◽  
Juan Ramon Delgado ◽  
Blanca Torres-Torres ◽  
Jesus Lopez-Peñalver ◽  
...  

1041 Background: Identification of gene expression-based breast cancer subtypes is considered a critical means of prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes occurring in breast cancer. However, the reproducibility of differential DNA methylation discoveries for cancer and the relationship between DNA methylation and aberrant gene expression have not been systematically analysed. The present study was undertaken to dissect the breast cancer methylome and to deliver specific epigenotypes associated with particular breast cancer subtypes. Methods: By using Real Time QMSPCR SYBR green we analyzed DNA methylation in regulatory regions of 107 pts with breast cancer and analyzed association with prognostics factor in triple negative breast cancer and methylation promoter ESR1, APC, E-Cadherin, Rar B and 14-3-3 sigma. Results: We identified novel subtype-specific epigenotypes that clearly demonstrate the differences in the methylation profiles of basal-like and human epidermal growth factor 2 (HER2)-overexpressing tumors. Of the cases, 37pts (40%) were Luminal A (LA), 32pts (33%) Luminal B (LB), 14pts (15%) Triple-negative (TN), and 9pts (10%) HER2+. DNA hypermethylation was highly inversely correlated with the down-regulation of gene expression. Methylation of this panel of promoter was found more frequently in triple negative and HER2 phenotype. ESR1 was preferably associated with TN(80%) and HER2+(60%) subtype. With a median follow up of 6 years, we found worse overall survival (OS) with more frequent ESR1 methylation gene(p>0.05), Luminal A;ESR1 Methylation OS at 5 years 81% vs 93% when was ESR1 Unmethylation. Luminal B;ESR1 Methylation 86% SG at 5 years vs 92% in Unmethylation ESR1. Triple negative;ESR1 Methylation SG at 5 years 75% vs 80% in unmethylation ESR1. HER2;ESR1 Methylation SG at 5 years was 66.7% vs 75% in unmethylation ESR1. Conclusions: Our results provide evidence that well-defined DNA methylation profiles enable breast cancer subtype prediction and support the utilization of this biomarker for prognostication and therapeutic stratification of patients with breast cancer.


2015 ◽  
Vol 138 (1) ◽  
pp. 87-97 ◽  
Author(s):  
Balázs Győrffy ◽  
Giulia Bottai ◽  
Thomas Fleischer ◽  
Gyöngyi Munkácsy ◽  
Jan Budczies ◽  
...  

10.29007/8xwn ◽  
2020 ◽  
Author(s):  
Isis Narvaez-Bandera ◽  
Wandaliz Torres-Garcia

Gene interactions play a fundamental role in the proneness to cancer. However, detect- ing and ranking these interactions is a complex problem due to the high dimensionality of genomic data. Hence, we aim to find patterns composed of multiple features to molecularly characterize breast cancer subtypes from the integration of different omics datasets using a data mining approach. To retrieve biological understanding from these computational results, we developed IBIF-RF (Importance Between Interactive Features using Random Forest), a new metric capable of assessing and holistically ranking the importance of genomic interactions without any prior knowledge of key feature combinations. A set of 247 top-performing features from transcriptomic, proteomic, methylation, and clinical data were used to investigate interactive patterns to classify breast cancer subtypes us- ing over 1150 samples. IBIF-RF metric allowed the extraction of 154312, 190481, and 463917 combinations of variables for TCGA, GSE20685, and GSE21653 datasets. Single genes, MLPH and FOXA1, were the most frequently identified variables across all datasets followed by some two-gene interactions such as CEP55-FOXA1 and FOXC1-THSD4. More- over, IBIF-RF metric allowed the definition of two sets of genes frequently found together (1: FOXA1, MLPH, and SIDT1, and 2: CEP55, ASPM, CENPL, AURKA, ESPL1, TTK, UBE2T, NCAPG, GMPS, NDC80, MYBL2, KIF18B, and EXO1).


2015 ◽  
Vol 51 ◽  
pp. S41
Author(s):  
B. Gyorffy ◽  
G. Bottai ◽  
T. Fleischer ◽  
G. Munkacsy ◽  
L. Paladini ◽  
...  

2021 ◽  
Author(s):  
Shipeng Shang ◽  
Xin Li ◽  
Yue Gao ◽  
Shuang Guo ◽  
Hanxiao Zhou ◽  
...  

Abstract Background Epigenetic clock based on DNA methylation can estimate the epigenetic age of tissue and cell that can describe the process of aging. However, the exploration of diseases by the epigenetic clock is still an uncharted territory. Our objective was to assess the role of the epigenetic clock in breast cancer. Methods In this study, DNA methylation data of breast tissue sample was download from TCGA and GEO database. DNA methylation level of CpG sites and age of samples was calculated by using pearson correlation test. Differentially expressed genes were identified using the limma package and Kruskal-Wallis test was used for the difference between cancer subtypes. Results We developed a workflow to construct the Breast Epigenetic Clock (BEpiC) that could accurately predict the chronological age of normal breast tissue. Furthermore, the BEpiC was applied to breast cancer to identify three breast cancer subtypes (including development, homeostasis, and mitosis) by using the deviation between epigenetic age and chronological age. Interestingly, the prognosis of the three breast cancer subtypes is significantly different. In addition, the three breast cancer subtypes had distinct differences in multiple immune cells and the mitosis subtype had the highest tumor mutation burden that was used to estimate response to checkpoint inhibitors. Conclusion Our model highlights that epigenetic age of breast cancer samples had an important impact on immunotherapy. We constructed a BEpiC web server (http://bio-bigdata.hrbmu.edu.cn/BEpiC/) where users submit DNA methylation data and age information to predict the epigenetic age of breast tissue and breast cancer subtypes. Trial registration Not applicable


Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry

Sign in / Sign up

Export Citation Format

Share Document